Physician profile
Claude B Smith
NPI 1619929676
$7,384.47
in general payments reported to CMS, 2019-2025
24 companies · $4,190 in 2025
The $4,190 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $250 · 2022: $940 · 2023: $588 · 2024: $727 · 2025: $4,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $3,602 · Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $3,601.50 |
| Food and Beverage | $1,903.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $3,623.28 | 2019-2025 | Neurostar Tms Therapy System |
| Lundbeck LLC | $544.03 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $441.34 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $375.59 | 2019-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $334.39 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $311.10 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $275.94 | 2022-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $266.78 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $227.12 | 2022-2024 | Caplyta |
| Tris Pharma INC | $160.37 | 2022-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $141.93 | 2022-2025 | Qelbree |
| Allergan, INC. | $118.56 | 2019-2020 | |
| Corium, LLC | $117.73 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $98.24 | 2025 | Invega Sustenna |
| Almatica Pharma LLC | $70.14 | 2023-2025 | Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $56.22 | 2019-2024 | Aplenzin |
| Shire North American Group INC | $48.54 | 2019 | |
| Axsome Therapeutics, INC. | $41.12 | 2023-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $31.24 | 2019 | |
| Owp Pharmaceuticals, INC. | $25.37 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.46 | 2024 | Hetlioz, Fanapt |
| Neos Therapeutics, LP | $20.76 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.